Premium
Effect of Nonnicotine Pharmacotherapy on Smoking Behavior
Author(s) -
Kotlyar Michael,
Golding Michael,
Hatsukami Dorothy K.,
Jamerson Brenda D.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.20.1530.34477
Subject(s) - moclobemide , bupropion , nortriptyline , buspirone , medicine , pharmacotherapy , nicotine replacement therapy , nicotine , pharmacology , smoking cessation , serotonin , psychiatry , antidepressant , amitriptyline , anxiety , receptor , pathology
Smoking‐related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1‐year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.